此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Phase III Study of AND017 to Evaluate Efficacy and Safety in NDD-CKD Associated Anemia

2026年11月15日 更新者:Kind Pharmaceuticals LLC

A Phase 3, Multi-center, Randomized, Open-Label, Active-Controlled, Efficacy and Safety Study of AND017 to Treat Anemia in Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients

This is a Phase 3, randomized, open-label, active-controlled study to evaluate the efficacy and safety of AND017 in non-dialysis-dependent (NDD)-CKD patients with anemia compared with the active control, erythropoietin stimulating agents (ESA).

研究概览

地位

尚未招聘

研究类型

介入性

注册 (估计的)

240

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Capable of providing signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

  • Body weight from 45-140 kg inclusive.

  • A diagnosis of CKD confirmed at screening, CKD stage 3, 4, or 5 defined by eGFR <60 mL/min/1.73 m2.

  • Prior ESA use and Hb levels:

    1. ESA-naïve: Defined as no use of any ESA treatment for at least 12 weeks before randomization; Mean of the two most recent Hb values during the screening period obtained at least 7 days apart must be ≥7.5 g/dL and <10.0 g/dL.
    2. ESA-treated: Defined as having received an approved ESA, administered intravenously or subcutaneously, for at least 6 weeks prior to randomization, with no change in ESA product and no treatment interruption exceeding two consecutive weeks; Mean of the two most recent Hb values during the screening period obtained at least 7 days apart must be 9.0-11.0 g/dL inclusive.
  • TSAT ≥20% or ferritin ≥100 ng/mL at screening test.

  • Serum folate and vitamin B12 ≥ lower limit normal (LLN) at screening test

  • Total bilirubin ≤1.5× upper limit normal (ULN). For Gilbert's Syndrom, <3×ULN.

  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3×ULN

  • No evidence of other causes of anemia caused by a pathologic process in the hematopoietic system, including intra- or extravascular hemolysis, or myelodysplasia

  • No other primary cause for anemia other than CKD.

Exclusion Criteria:

  • Concurrent retinal neovascular lesions requiring treatment including proliferative diabetic retinopathy, exudative age-related macular degeneration, retinal vein occlusion, macular edema, etc.
  • Chronic inflammatory disease other than glomerulonephritis that could impact erythropoiesis or concurrent autoimmune disease with inflammatory symptoms.
  • History of gastric/intestinal resection considered to affect the absorption of drugs in the gastrointestinal tract or concurrent symptomatic gastroparesis despite being on treatment.
  • Clinically significant bleeding within 4 weeks of first dose; bleeding diathesis or risk of bleeding that has not been medically or surgically corrected at least 4 weeks prior to first dose of study drug.
  • History or concurrent hemosiderosis, hemochromatosis or hyper-coagulable condition.
  • Uncontrolled hypertension, defined as patients with hypertension having more than one of three systolic blood pressure (SBP) >180 mmHg, or diastolic blood pressure (DBP) >110 mmHg during the screening period.
  • History of stroke, transient ischemic attack, myocardial infarction, thromboembolic event , pulmonary embolism, or lung infarction within 24 weeks before the screening assessment.
  • Participants with a history of significant liver disease or active liver disease.
  • History of a seizure disorder or any occurrence of seizures in the past.
  • History or concurrent malignancy, except for cancers determined to be cured or in remission for ≥5 years, curatively resected basal cell or squamous cell carcinoma, cervical cancer in situ.
  • History of a seizure disorder or any occurrence of seizures in the past.
  • History or concurrent malignancy, except for cancers determined to be cured or in remission for ≥5 years, curatively resected basal cell or squamous cell carcinoma, cervical cancer in situ.
  • Having undergone blood transfusion and/or a surgical procedure that caused major blood loss within 8 weeks before the screening assessment
  • Participants that have major surgery planned during the study period.
  • Any prior functioning organ transplant or a scheduled organ transplantation, or anephric.
  • Serum albumin (ALB) < 2.5 g/dL at screening test.
  • Positive for hepatitis B surface antigen or anti-hepatitis C virus antibody at the screening assessment, or positive for human immunodeficiency virus in a past test.
  • Having received any investigational drug in an interventional clinical trial within 5 weeks before the randomization.
  • A known history of allergic reactions to ESA treatment.
  • History of serious drug allergies.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:AND017

AND017 capsules administered orally with a starting dose of 8 mg TIW for ESA naive patients or 10 mg TIW for ESA treated patients

有源比较器:ESA

ESA injection and dose based on package insert and local practice

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
The mean Hb levels averaged over Week 25-29
大体时间:Week 25 to Week 29

Evaluate the efficacy of AND017 for treatment of anemia in patients with NDD-CKD

Week 25 to Week 29

次要结果测量

结果测量
措施说明
大体时间
Percentage of responders over the main treatment period
大体时间:Baseline, at Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29 or end of treatment

defined as patients who meet either of the following criteria: For patients with baseline Hb 9.0 g/dL: mean Hb ≥ 10.0 g/dL during Weeks 25-29 and a change from baseline ≥ -1.0 g/dL during Weeks 25-29; For patients with baseline Hb < 9.0 g/dL: an increase in Hb from baseline ≥ 1.0 g/dL during Weeks 3-29

Baseline, at Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29 or end of treatment
Percentage of patients with mean Hb ≥ 10.0 g/dL averaged over Weeks 5-29
大体时间:Week 5, 7, 9, 13, 17, 21, 25, 29 or end of treatment

Percentage of patients with mean Hb ≥ 10.0 g/dL averaged over Weeks 5-29

Week 5, 7, 9, 13, 17, 21, 25, 29 or end of treatment
The percentage of response visits over the entire study treatment
大体时间:Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment

Response visit is defined as after first reaching ≥ 10.0 g/dL, Hb maintained within the target range of 10.0-11.0 g/dL

Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
The cumulative incidence of Hb non-response over Weeks 5-29
大体时间:Baseline, Week 5, 7, 9, 13, 17, 21, 25, 29 or end of treatment

Non-response is defined as Hb < 10.0 g/dL and an increase from baseline < 1.0 g/dL

Baseline, Week 5, 7, 9, 13, 17, 21, 25, 29 or end of treatment
Change from baseline in serum iron over the entire treatment period
大体时间:Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Change from baseline in ferritin over the entire treatment period
大体时间:Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Change from baseline in transferrin over the entire treatment period
大体时间:Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Change from baseline in transferrin saturation over the entire treatment period
大体时间:Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Change from baseline in total iron binding capacity over the entire treatment period
大体时间:Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
The percentage of patients received intravenous iron treatment during the entire study
大体时间:Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
During the entire treatment period, the mean weekly dose of intravenous iron treatment (mg)
大体时间:Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
During the entire treatment period, the time to first initiation of intravenous iron treatment (Day)
大体时间:Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Change from baseline in total cholesterol over the entire treatment period
大体时间:Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Change from baseline in low density lipoprotein over the entire treatment period
大体时间:Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Change from baseline in high density lipoprotein over the entire treatment period
大体时间:Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Change from baseline in triglycerides over the entire treatment period
大体时间:Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2027年2月1日

初级完成 (估计的)

2027年12月1日

研究完成 (估计的)

2028年6月1日

研究注册日期

首次提交

2026年11月15日

首先提交符合 QC 标准的

2026年11月15日

首次发布 (实际的)

2026年11月20日

研究记录更新

最后更新发布 (实际的)

2026年11月20日

上次提交的符合 QC 标准的更新

2026年11月15日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • AND017-US-303

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅